Hypothesis

Rapamycin improves endothelial function by inducing mitophagy that selectively removes damaged mitochondria, thereby reducing ROS and restoring eNOS coupling, while leaving senescent cell markers largely unchanged.

Mechanistic Rationale

• Rapamycin inhibits mTORC1, which activates ULK1‑dependent autophagy and, under stress, promotes PINK1/Parkin‑mediated mitophagy (1).
• Senescent endothelial cells exhibit persistent mTORC1 signaling due to defective nutrient sensing, yet their mitochondria are often depolarized and ROS‑producing (2).
• By enhancing mitophagy, rapamycin would lower mitochondrial ROS, decreasing superoxide that scavenges NO and drives eNOS uncoupling (3; 4).
• Reduced ROS would increase NO bioavailability and diminish NF‑κB activation, lowering ICAM‑1 expression without affecting the core senescent program (p16^Ink4a^, SASP) (5).
• This creates a “pseudo‑quiescent” endothelial state: improved vasodilatory capacity and lower inflammation, but the cells remain senescent and resistant to clearance (6).

Testable Predictions

1. In vivo: Aged mice treated with rapamycin for 8 weeks will show:
   • ↑ mitochondrial citrate synthase activity and ↓ MitoSOX fluorescence in isolated aortic endothelium.
   • ↑ NO‑dependent vasodilation (acetylcholine response) and ↓ ICAM‑1 immunostaining.
   • No significant change in p16^Ink4a^+ or SA‑β‑gal+ endothelial cell frequency versus vehicle.
2. In vitro: Human umbilical vein endothelial cells (HUVECs) rendered senescent by irradiation will, after rapamycin exposure:
   • Exhibit increased LC3‑II colocalization with mitochondrial markers (Mitotracker) and elevated PINK1/Parkin ubiquitination.
   • Show reduced mitochondrial ROS (MitoSOX) and increased DAF‑FM NO signal.
   • Maintain elevated SASP IL‑6/IL‑8 secretion and p21^Cip1^ expression.
3. Falsification: If rapamycin fails to reduce mitochondrial ROS or improve NO coupling despite autophagy induction, or if senescent cell burden declines in parallel, the hypothesis is refuted.

Experimental Approach

• Use mitochondrial‑targeted mito‑Keima to quantify mitophagy flux in endothelium.
• Combine rapamycin with a mitophagy inhibitor (e.g., Mdivi‑1) to test dependence on mitochondrial clearance.
• Compare outcomes to senolytic (navitoclax) treatment to dissociate effects on mitochondrial health versus senescent cell removal.

Implications

If validated, this would reposition rapamycin’s vascular benefit as a hormetic, mitochondria‑focused stress adaptation rather than senescent cell clearance, explaining why lifespan extends without reversing atherosclerotic lesions. It would also suggest that combining rapamycin with agents that promote senescent cell apoptosis (senolytics) is necessary for true vascular rejuvenation.